Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Humaira Hussein
Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT-2is) and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Patients With Type 2 Diabetes: A Systematic Review and Network Meta-Analysis Study Protocol
BMJ Open
Medicine
Related publications
Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
Diabetes Technology and Therapeutics
Medicine
Endocrinology
Medical Laboratory Technology
Metabolism
Diabetes
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: A Systematic Review and Mixed-Treatment Comparison Analysis
Diabetes, Obesity and Metabolism
Internal Medicine
Endocrinology
Metabolism
Diabetes
Use of Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections in Type 2 Diabetes Patients: A Systematic Review
Revista da Associacao Medica Brasileira
Medicine
The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis
PLoS ONE
Multidisciplinary
Pdb112 - Treatment and Dosing Patterns Among Patients With Type 2 Diabetes (T2d) Initiating Glucagon-Like Peptide-1 Receptor Agonists (Glp-1 Ras) in Several Countries
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pdb12 - Cardiovascular Safety of Empagliflozin Versus Glucagon-Like Peptide-1 (Glp-1) Receptor Agonists: Systematic Literature Review and Indirect Comparisons
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Glucagon-Like Peptide 1 Receptor Agonists: A New Approach to Type 2 Diabetes Management
South African Family Practice
Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes
Diabetes Care
Internal Medicine
Endocrinology
Advanced
Metabolism
Specialized Nursing
Diabetes
Ertugliflozin: A Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitor for Glycemic Control in Type 2 Diabetes
Therapeutics and Clinical Risk Management
